{"protocolSection":{"identificationModule":{"nctId":"NCT00329901","orgStudyIdInfo":{"id":"V59P11"},"secondaryIdInfos":[{"id":"2005-005519-12","type":"EUDRACT_NUMBER"},{"id":"2005","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2005"}],"organization":{"fullName":"Novartis","class":"INDUSTRY"},"briefTitle":"Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years","officialTitle":"A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis (Tdap) Vaccine and Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Acellular Pertussis (Tdap) Vaccine, or One Dose of Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years"},"statusModule":{"statusVerifiedDate":"2014-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-04"},"primaryCompletionDateStruct":{"date":"2007-05","type":"ACTUAL"},"completionDateStruct":{"date":"2007-12","type":"ACTUAL"},"studyFirstSubmitDate":"2006-05-23","studyFirstSubmitQcDate":"2006-05-23","studyFirstPostDateStruct":{"date":"2006-05-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-08-27","resultsFirstSubmitQcDate":"2014-06-16","resultsFirstPostDateStruct":{"date":"2014-06-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-06-16","lastUpdatePostDateStruct":{"date":"2014-06-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novartis Vaccines","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years"},"conditionsModule":{"conditions":["Meningococcal Disease","Meningococcal Meningitis"],"keywords":["Meningitis","healthy subject","vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":1072,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tdap + MenACWY-CRM","type":"EXPERIMENTAL","description":"Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms","interventionNames":["Biological: Meningococcal ACWY conjugate vaccine (MenACWY-CRM)","Biological: Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)"]},{"label":"Tdap + saline","type":"EXPERIMENTAL","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms","interventionNames":["Biological: Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)","Biological: saline placebo"]},{"label":"MenACWY-CRM + saline","type":"EXPERIMENTAL","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms","interventionNames":["Biological: Meningococcal ACWY conjugate vaccine (MenACWY-CRM)","Biological: saline placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal ACWY conjugate vaccine (MenACWY-CRM)","armGroupLabels":["MenACWY-CRM + saline","Tdap + MenACWY-CRM"]},{"type":"BIOLOGICAL","name":"Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)","armGroupLabels":["Tdap + MenACWY-CRM","Tdap + saline"]},{"type":"BIOLOGICAL","name":"saline placebo","description":"4.5 mg sodium chloride per 0.5 ml dose","armGroupLabels":["MenACWY-CRM + saline","Tdap + saline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given Concomitantly With Saline Placebo","description":"To demonstrate that the immunogenicity of one injection of Tdap vaccine, concomitantly administered with MenACWY-CRM vaccine, is not inferior to that of one injection of Tdap vaccine, concomitantly administered with saline placebo, in terms of\n\n1. the percentage of subjects with antibody levels against diphtheria toxin ≥ 1.0 IU/mL and against tetanus toxin ≥ 1.0 IU/mL and\n2. the percentage of subjects with at least 4 fold increase in antibody levels against pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN) at 1 month after immunization, as measured by enzyme linked immunosorbent assay (ELISA).","timeFrame":"1 month after vaccination (Day 29)"}],"secondaryOutcomes":[{"measure":"Percentage of Subjects With Anti-diphtheria and Anti-tetanus Concentrations ≥ 0.1 IU/mL When Tdap is Administered Concomitantly With MenACWY-CRM Vaccine Compared to Tdap Given Concomitantly With Saline Placebo","description":"The percentage of subjects with anti-diphtheria and anti-tetanus concentrations ≥ 0.1 IU/mL (as measured by ELISA) following concomitant administration of Tdap vaccine with MenACWY-CRM vaccine as compared to when Tdap was given concomitantly with saline placebo.","timeFrame":"1 month after vaccination (Day 29)"},{"measure":"Geometric Mean Concentrations (GMCs) of Antibodies Against Diphtheria,Tetanus and Pertussis Antigens After Concomitant Administration of Tdap With MenACWY-CRM Compared to Tdap Given Concomitantly With Saline Placebo","description":"The geometric mean concentrations of antibodies ≥ 0.1 IU/mL against diphtheria, tetanus and pertussis (PT, FHA and PRN) antigens in subjects, as measured by ELISA, following concomitant administration of Tdap with MenACWY-CRM as compared to when Tdap given concomitantly with saline placebo.","timeFrame":"1 month after vaccination (Day 29)"},{"measure":"Geometric Mean Ratios of Antibody Concentrations Against Diphtheria,Tetanus and Pertussis Antigens When Tdap is Administered Concomitantly With MenACWY-CRM Vaccine Compared to Tdap Given Concomitantly With Saline Placebo","description":"The geometric mean ratios (GMRs- day 29/day 1) of post-vaccination versus pre- vaccination antibody concentrations against diptheria, tetanus and pertussis (PT, FHA and PRN) antigens following concomitant administration of Tdap vaccine with MenACWY-CRM vaccine as compared to when Tdap was given concomitantly with saline placebo.","timeFrame":"1 month after vaccination (Day 29)"},{"measure":"Percentage of Subjects With Serum Bactericidal Antibody Titers ≥1:4 and ≥1:8, When MenACWY-CRM is Concomitantly Administered With Tdap Vaccine Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The percentage of subjects with serum bactericidal antibody titers(hSBA) ≥ 1:4 and ≥ 1:8 against Neisseria meningitidis serogroups A,C,W and Y,following concomitant administration of MenACWY-CRM vaccine with Tdap vaccine as compared to when MenACWY-CRM was given concomitantly with saline placebo.\n\nThe serum bactericidal antibodies directed against N.meningitidis serogroup A, C, W and Y, are measured by human complement Serum Bactericidal Assay (hSBA).","timeFrame":"1 month after vaccination (Day 29)"},{"measure":"The hSBA Geometric Mean Titers Against N.Meningitidis Serogroups A,C,W and Y, When MenACWY-CRM is Concomitantly Administered With Tdap Vaccine Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The hSBA geometric mean titers (GMTs) against N.meningitidis serogroups A,C,W and Y, at baseline and at one month, following concomitant administration of MenACWY-CRM vaccine with Tdap vaccine, as compared to when MenACWY-CRM was given concomitantly with saline placebo.","timeFrame":"1 month after vaccination (Day 29)"},{"measure":"Geometric Mean Ratios of hSBA Titers Against N.Meningitidis Serogroups A,C,W and Y, When MenACWY-CRM is Concomitantly Administered With Tdap Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The geometric mean ratios (GMRs-day 29/day1)of post-vaccination versus pre- vaccination hSBA titers against N.meningitidis serogroups A,C,W and Y, when MenACWY-CRM vaccine is concomitantly administered with Tdap vaccine as compared to when MenACWY-CRM was given concomitantly with saline placebo.","timeFrame":"1 month after vaccination (Day 29)"},{"measure":"Percentage of Subjects With hSBA Seroresponse, When MenACWY-CRM is Concomitantly Administered With Tdap Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The percentage of subjects showing an hSBA seroresponse against N.meningitidis serogroups A,C,W and Y, following concomitant administration of MenACWY-CRM vaccine with Tdap vaccine as compared to when MenACWY-CRM was given concomitantly with saline placebo.\n\nSeroresponse to MenACWY-CRM is defined as a pre-vaccination hSBA titer \\< 1:4 to a post-vaccination hSBA titer of ≥ 1:8 or a pre-vaccination hSBA titer ≥ 1:4 to a post-vaccination titer of at least four times the baseline hSBA titer.","timeFrame":"1 month after vaccination (Day 29)"},{"measure":"Number of Subjects With Solicited Local and Systemic Adverse Events When Tdap is Concomitantly Administered With MenACWY-CRM Compared to When MenACWY-CRM is Concomitantly Administered With Saline Placebo","description":"The number of subjects reporting solicited local and systemic reactions following concomitant administration of MenACWY-CRM vaccine and Tdap vaccine as compared to when MenACWY-CRM vaccine was concomitantly administered with saline placebo.","timeFrame":"Day 1-7 after any vaccination"},{"measure":"Number of Subjects With Solicited Local and Systemic Adverse Events When Tdap is Concomitantly Administered With MenACWY-CRM Compared to When Tdap is Concomitantly Administered With Saline Placebo","description":"The number of subjects reporting solicited local and systemic reactions following concomitant administration of MenACWY-CRM vaccine and Tdap vaccine as compared to when Tdap was concomitantly administered with saline placebo","timeFrame":"Day 1-7 after any vaccination"},{"measure":"Number of Subjects With Unsolicited Adverse Events When Tdap is Concomitantly Administered With MenACWY-CRM Compared to MenACWY-CRM or Tdap Concomitantly Administered With Saline Placebo","description":"The number of subjects reporting any unsolicited adverse events (AEs) when Tdap is concomitantly administered with MenACWY-CRM as compared to when MenACWY-CRM vaccine or Tdap vaccine was concomitantly administered with saline placebo.","timeFrame":"Throughout the study (Day 1 to Day 181)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female 11-25 years old healthy subjects;\n* who had received the primary immunization with a vaccine containing DT or Tdap antigens and a T, Td, or Tdap booster injection at least 5 years prior to study entry\n\nExclusion Criteria:\n\n* previous ascertained or suspected disease caused by N. meningitidis\n* previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)\n* serious acute, chronic or progressive disease\n* history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine component\n* known or suspected impairment/alteration of immune function, either congenital or acquired","healthyVolunteers":true,"sex":"ALL","minimumAge":"11 Years","maximumAge":"25 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Novartis Vaccines - Information Services","affiliation":"Novartis Vaccines & Diagnostics","role":"STUDY_CHAIR"}],"locations":[{"city":"Andria","country":"Italy","geoPoint":{"lat":41.23117,"lon":16.29797}},{"city":"Catania","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"city":"Chieti","country":"Italy","geoPoint":{"lat":42.34827,"lon":14.16494}},{"city":"Ferrara","country":"Italy","geoPoint":{"lat":44.83804,"lon":11.62057}},{"city":"Genova","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"city":"Lanciano","country":"Italy","geoPoint":{"lat":42.22718,"lon":14.39024}},{"city":"Massafra","country":"Italy","geoPoint":{"lat":40.58618,"lon":17.11635}},{"city":"Modena","country":"Italy","geoPoint":{"lat":44.64783,"lon":10.92539}},{"city":"Novara","country":"Italy","geoPoint":{"lat":45.44694,"lon":8.62118}},{"city":"Palermo","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"city":"Pieve Di Soligo (TV)","country":"Italy","geoPoint":{"lat":45.89836,"lon":12.17128}},{"city":"Roma","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"city":"Sassari","country":"Italy","geoPoint":{"lat":40.72586,"lon":8.55552}},{"city":"Taranto","country":"Italy","geoPoint":{"lat":40.46438,"lon":17.24707}}]},"referencesModule":{"references":[{"pmid":"20164251","type":"RESULT","citation":"Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull PM, Ceddia F. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol. 2010 Apr;17(4):537-44. doi: 10.1128/CVI.00436-09. Epub 2010 Feb 17."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All enrolled subjects participated in the trial.","recruitmentDetails":"Subjects were recruited from 14 centers in Italy.","groups":[{"id":"FG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"FG001","title":"Tdap + Saline","description":"Subjects received Tdap vaccine and saline (placebo)concomitantly, in separate arms"},{"id":"FG002","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"361"},{"groupId":"FG001","numSubjects":"354"},{"groupId":"FG002","numSubjects":"357"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"352"},{"groupId":"FG001","numSubjects":"349"},{"groupId":"FG002","numSubjects":"353"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Unable to classify","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Baseline Characteristics are summarized for all enrolled population","groups":[{"id":"BG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"BG001","title":"Tdap + Saline","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms"},{"id":"BG002","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"361"},{"groupId":"BG001","value":"354"},{"groupId":"BG002","value":"357"},{"groupId":"BG003","value":"1072"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14.4","spread":"3.4"},{"groupId":"BG001","value":"14.1","spread":"3.2"},{"groupId":"BG002","value":"14.3","spread":"3.2"},{"groupId":"BG003","value":"14.3","spread":"3.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"165"},{"groupId":"BG003","value":"518"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"190"},{"groupId":"BG002","value":"192"},{"groupId":"BG003","value":"554"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given Concomitantly With Saline Placebo","description":"To demonstrate that the immunogenicity of one injection of Tdap vaccine, concomitantly administered with MenACWY-CRM vaccine, is not inferior to that of one injection of Tdap vaccine, concomitantly administered with saline placebo, in terms of\n\n1. the percentage of subjects with antibody levels against diphtheria toxin ≥ 1.0 IU/mL and against tetanus toxin ≥ 1.0 IU/mL and\n2. the percentage of subjects with at least 4 fold increase in antibody levels against pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN) at 1 month after immunization, as measured by enzyme linked immunosorbent assay (ELISA).","populationDescription":"Analysis was done on the per-protocol population i.e all subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to unblinding","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap+MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"Tdap+Saline","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"350"},{"groupId":"OG001","value":"345"}]}],"classes":[{"title":"Day 1 (diphtheria)","categories":[{"measurements":[{"groupId":"OG000","value":"4","lowerLimit":"2","upperLimit":"7"},{"groupId":"OG001","value":"5","lowerLimit":"3","upperLimit":"7"}]}]},{"title":"Day 29 (diphtheria)","categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"91","upperLimit":"96"},{"groupId":"OG001","value":"85","lowerLimit":"80","upperLimit":"88"}]}]},{"title":"Day 1 (tetanus )","categories":[{"measurements":[{"groupId":"OG000","value":"25","lowerLimit":"20","upperLimit":"30"},{"groupId":"OG001","value":"36","lowerLimit":"31","upperLimit":"42"}]}]},{"title":"Day 29 (tetanus )","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"99","upperLimit":"100"},{"groupId":"OG001","value":"99","lowerLimit":"98","upperLimit":"100"}]}]},{"title":"Day 29 (PT) 4-fold increase (N=286, 287)","categories":[{"measurements":[{"groupId":"OG000","value":"76","lowerLimit":"70","upperLimit":"80"},{"groupId":"OG001","value":"81","lowerLimit":"76","upperLimit":"85"}]}]},{"title":"Day 29 (FHA)4-fold increase (N=286, 287)","categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"78","upperLimit":"87"},{"groupId":"OG001","value":"86","lowerLimit":"82","upperLimit":"90"}]}]},{"title":"Day 29 (PRN) 4-fold increase (N=285, 287)","categories":[{"measurements":[{"groupId":"OG000","value":"84","lowerLimit":"79","upperLimit":"88"},{"groupId":"OG001","value":"91","lowerLimit":"87","upperLimit":"94"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of anti-diphtheria immune response following concomitant administration of Tdap with MenACWY-CRM as compared to Tdap given with placebo saline","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response to Tdap + MenACWY-CRM was considered non-inferior to that of Tdap+saline if for all five antigens (diphtheria, tetanus, PT, FHA, PRN) the lower limit of the 95% CI of the difference \\[(Tdap + MenACWY-CRM) minus(Tdap + saline)\\] was greater than -10, at 1 month (Day 29) after vaccination","paramType":"Vaccine Group difference","paramValue":"9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5","ciUpperLimit":"14"},{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of anti-tetanus immune response following concomitant administration of Tdap with MenACWY-CRM compared to Tdap given concomitantly with saline placebo","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response to Tdap + MenACWY-CRM was considered non-inferior to that of Tdap+saline if for all five antigens (diphtheria, tetanus, PT, FHA, PRN) the lower limit of the 95% CI of the difference \\[(Tdap + MenACWY-CRM) minus(Tdap + saline)\\] was greater than -10, at 1 month (Day 29) after vaccination","paramType":"Vaccine Group Difference","paramValue":"1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1","ciUpperLimit":"2"},{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of anti-PT antigen immune response following concomitant administration of Tdap with MenACWY as compared to Tdap given concomitantly with saline placebo","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response to Tdap + MenACWY-CRM was considered non-inferior to that of Tdap+saline if for all five antigens (diphtheria, tetanus, PT, FHA, PRN) the lower limit of the 95% CI of the difference \\[(Tdap + MenACWY-CRM) minus (Tdap + saline)\\] was greater than -10, at 1 month (Day 29) after vaccination","paramType":"Vaccine Group difference","paramValue":"-5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12","ciUpperLimit":"1"},{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of anti-FHA antigen immune response following concomitant administration of Tdap with MenACWY as compared to Tdap given concomitantly with saline placebo","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response to Tdap + MenACWY-CRM was considered non-inferior to that of Tdap+saline if for all five antigens (diphtheria, tetanus, PT, FHA, PRN) the lower limit of the 95% CI of the difference \\[(Tdap + MenACWY-CRM) minus (Tdap + saline)\\] was greater than -10, at 1 month (Day 29) after vaccination","paramType":"Vaccine Group Difference","paramValue":"-3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9","ciUpperLimit":"3"},{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of anti-PRN antigen immune response following concomitant administration of Tdap with MenACWY as compared to Tdap given concomitantly with saline placebo","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response to Tdap + MenACWY-CRM was considered non-inferior to that of Tdap+saline if for all five antigens (diphtheria, tetanus, PT, FHA, PRN) the lower limit of the 95% CI of the difference \\[(Tdap + MenACWY-CRM) minus (Tdap + saline)\\] was greater than -10, at 1 month (Day 29) after vaccination","paramType":"Vaccine Group Difference","paramValue":"-7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13","ciUpperLimit":"-2"}]},{"type":"SECONDARY","title":"Percentage of Subjects With Anti-diphtheria and Anti-tetanus Concentrations ≥ 0.1 IU/mL When Tdap is Administered Concomitantly With MenACWY-CRM Vaccine Compared to Tdap Given Concomitantly With Saline Placebo","description":"The percentage of subjects with anti-diphtheria and anti-tetanus concentrations ≥ 0.1 IU/mL (as measured by ELISA) following concomitant administration of Tdap vaccine with MenACWY-CRM vaccine as compared to when Tdap was given concomitantly with saline placebo.","populationDescription":"Analysis was done on per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap+MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"Tdap+Saline","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"350"},{"groupId":"OG001","value":"345"}]}],"classes":[{"title":"Day 1 (diphtheria)","categories":[{"measurements":[{"groupId":"OG000","value":"55","lowerLimit":"50","upperLimit":"60"},{"groupId":"OG001","value":"63","lowerLimit":"57","upperLimit":"68"}]}]},{"title":"Day 29 (diphtheria)","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"99","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"98","upperLimit":"100"}]}]},{"title":"Day 1 (tetanus)","categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"95","upperLimit":"99"},{"groupId":"OG001","value":"97","lowerLimit":"95","upperLimit":"99"}]}]},{"title":"Day 29 (tetanus)","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"99","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"99","upperLimit":"100"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations (GMCs) of Antibodies Against Diphtheria,Tetanus and Pertussis Antigens After Concomitant Administration of Tdap With MenACWY-CRM Compared to Tdap Given Concomitantly With Saline Placebo","description":"The geometric mean concentrations of antibodies ≥ 0.1 IU/mL against diphtheria, tetanus and pertussis (PT, FHA and PRN) antigens in subjects, as measured by ELISA, following concomitant administration of Tdap with MenACWY-CRM as compared to when Tdap given concomitantly with saline placebo.","populationDescription":"Analysis was done on per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap+ MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"Tdap+Saline","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"350"},{"groupId":"OG001","value":"345"}]}],"classes":[{"title":"Day 1 (diptheria)","categories":[{"measurements":[{"groupId":"OG000","value":"0.11","lowerLimit":"0.085","upperLimit":"0.14"},{"groupId":"OG001","value":"0.12","lowerLimit":"0.096","upperLimit":"0.16"}]}]},{"title":"Day 29 (diptheria)","categories":[{"measurements":[{"groupId":"OG000","value":"7.96","lowerLimit":"6.19","upperLimit":"10"},{"groupId":"OG001","value":"2.77","lowerLimit":"2.15","upperLimit":"3.57"}]}]},{"title":"Day 1 (tetanus)","categories":[{"measurements":[{"groupId":"OG000","value":"0.62","lowerLimit":"0.5","upperLimit":"0.76"},{"groupId":"OG001","value":"0.75","lowerLimit":"0.61","upperLimit":"0.92"}]}]},{"title":"Day 29 (tetanus)","categories":[{"measurements":[{"groupId":"OG000","value":"12","lowerLimit":"9.84","upperLimit":"14"},{"groupId":"OG001","value":"15","lowerLimit":"13","upperLimit":"18"}]}]},{"title":"Day 1 (PT ) (N=286,287)","categories":[{"measurements":[{"groupId":"OG000","value":"2.68","lowerLimit":"1.97","upperLimit":"3.66"},{"groupId":"OG001","value":"2.85","lowerLimit":"2.1","upperLimit":"3.86"}]}]},{"title":"Day 29 (PT) (N=286,287)","categories":[{"measurements":[{"groupId":"OG000","value":"62","lowerLimit":"52","upperLimit":"74"},{"groupId":"OG001","value":"79","lowerLimit":"66","upperLimit":"93"}]}]},{"title":"Day 1 (FHA) (N=286,287)","categories":[{"measurements":[{"groupId":"OG000","value":"15","lowerLimit":"13","upperLimit":"18"},{"groupId":"OG001","value":"17","lowerLimit":"14","upperLimit":"20"}]}]},{"title":"Day 29 (FHA) (N=286,287)","categories":[{"measurements":[{"groupId":"OG000","value":"186","lowerLimit":"165","upperLimit":"209"},{"groupId":"OG001","value":"219","lowerLimit":"194","upperLimit":"246"}]}]},{"title":"Day 1 (PRN) (N=285,287)","categories":[{"measurements":[{"groupId":"OG000","value":"6.45","lowerLimit":"5.18","upperLimit":"8.03"},{"groupId":"OG001","value":"8.7","lowerLimit":"7.01","upperLimit":"11"}]}]},{"title":"Day 29 (PRN) (N=285,287)","categories":[{"measurements":[{"groupId":"OG000","value":"157","lowerLimit":"131","upperLimit":"189"},{"groupId":"OG001","value":"254","lowerLimit":"211","upperLimit":"304"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratios of Antibody Concentrations Against Diphtheria,Tetanus and Pertussis Antigens When Tdap is Administered Concomitantly With MenACWY-CRM Vaccine Compared to Tdap Given Concomitantly With Saline Placebo","description":"The geometric mean ratios (GMRs- day 29/day 1) of post-vaccination versus pre- vaccination antibody concentrations against diptheria, tetanus and pertussis (PT, FHA and PRN) antigens following concomitant administration of Tdap vaccine with MenACWY-CRM vaccine as compared to when Tdap was given concomitantly with saline placebo.","populationDescription":"Analysis was done on per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap+ MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"Tdap+Saline","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"350"},{"groupId":"OG001","value":"345"}]}],"classes":[{"title":"diphtheria","categories":[{"measurements":[{"groupId":"OG000","value":"72","lowerLimit":"58","upperLimit":"91"},{"groupId":"OG001","value":"22","lowerLimit":"18","upperLimit":"28"}]}]},{"title":"tetanus","categories":[{"measurements":[{"groupId":"OG000","value":"19","lowerLimit":"14","upperLimit":"25"},{"groupId":"OG001","value":"20","lowerLimit":"15","upperLimit":"26"}]}]},{"title":"PT (N=286,287)","categories":[{"measurements":[{"groupId":"OG000","value":"23","lowerLimit":"18","upperLimit":"30"},{"groupId":"OG001","value":"28","lowerLimit":"21","upperLimit":"36"}]}]},{"title":"FHA (N=286,287)","categories":[{"measurements":[{"groupId":"OG000","value":"12","lowerLimit":"10","upperLimit":"14"},{"groupId":"OG001","value":"13","lowerLimit":"11","upperLimit":"15"}]}]},{"title":"PRN (N=285,287)","categories":[{"measurements":[{"groupId":"OG000","value":"24","lowerLimit":"20","upperLimit":"30"},{"groupId":"OG001","value":"29","lowerLimit":"24","upperLimit":"35"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Serum Bactericidal Antibody Titers ≥1:4 and ≥1:8, When MenACWY-CRM is Concomitantly Administered With Tdap Vaccine Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The percentage of subjects with serum bactericidal antibody titers(hSBA) ≥ 1:4 and ≥ 1:8 against Neisseria meningitidis serogroups A,C,W and Y,following concomitant administration of MenACWY-CRM vaccine with Tdap vaccine as compared to when MenACWY-CRM was given concomitantly with saline placebo.\n\nThe serum bactericidal antibodies directed against N.meningitidis serogroup A, C, W and Y, are measured by human complement Serum Bactericidal Assay (hSBA).","populationDescription":"Analysis was done on per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"Day 1 (Men A) hSBA ≥ 1:4","categories":[{"measurements":[{"groupId":"OG000","value":"3","lowerLimit":"1","upperLimit":"7"},{"groupId":"OG001","value":"5","lowerLimit":"2","upperLimit":"10"}]}]},{"title":"Day 29 (Men A) hSBA ≥ 1:4","categories":[{"measurements":[{"groupId":"OG000","value":"79","lowerLimit":"71","upperLimit":"86"},{"groupId":"OG001","value":"83","lowerLimit":"75","upperLimit":"89"}]}]},{"title":"Day 1 (Men C) hSBA ≥ 1:4 (N=118,124)","categories":[{"measurements":[{"groupId":"OG000","value":"36","lowerLimit":"28","upperLimit":"46"},{"groupId":"OG001","value":"30","lowerLimit":"22","upperLimit":"39"}]}]},{"title":"Day 29 (Men C) hSBA ≥ 1:4 (N=118,124)","categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"88","upperLimit":"98"},{"groupId":"OG001","value":"90","lowerLimit":"84","upperLimit":"95"}]}]},{"title":"Day 1 (Men W) hSBA ≥ 1:4 (N=116,124)","categories":[{"measurements":[{"groupId":"OG000","value":"57","lowerLimit":"47","upperLimit":"66"},{"groupId":"OG001","value":"56","lowerLimit":"47","upperLimit":"65"}]}]},{"title":"Day 29 (Men W) hSBA ≥ 1:4 (N=116,124)","categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"93","upperLimit":"99"},{"groupId":"OG001","value":"97","lowerLimit":"92","upperLimit":"99"}]}]},{"title":"Day 1 (Men Y) hSBA ≥ 1:4 (N=117,125)","categories":[{"measurements":[{"groupId":"OG000","value":"47","lowerLimit":"38","upperLimit":"56"},{"groupId":"OG001","value":"42","lowerLimit":"33","upperLimit":"51"}]}]},{"title":"Day 29 (Men Y) hSBA ≥ 1:4 (N=117,125)","categories":[{"measurements":[{"groupId":"OG000","value":"96","lowerLimit":"90","upperLimit":"99"},{"groupId":"OG001","value":"97","lowerLimit":"92","upperLimit":"99"}]}]},{"title":"Day 1 (Men A) hSBA ≥ 1:8","categories":[{"measurements":[{"groupId":"OG000","value":"2","lowerLimit":"0","upperLimit":"6"},{"groupId":"OG001","value":"4","lowerLimit":"1","upperLimit":"9"}]}]},{"title":"Day 29 (Men A) hSBA ≥ 1:8","categories":[{"measurements":[{"groupId":"OG000","value":"74","lowerLimit":"65","upperLimit":"82"},{"groupId":"OG001","value":"80","lowerLimit":"72","upperLimit":"87"}]}]},{"title":"Day 1 (Men C) hSBA ≥ 1:8 (N=118,124)","categories":[{"measurements":[{"groupId":"OG000","value":"25","lowerLimit":"17","upperLimit":"33"},{"groupId":"OG001","value":"25","lowerLimit":"18","upperLimit":"34"}]}]},{"title":"Day 29 (Men C) hSBA ≥ 1:8 (N=118,124)","categories":[{"measurements":[{"groupId":"OG000","value":"92","lowerLimit":"86","upperLimit":"96"},{"groupId":"OG001","value":"88","lowerLimit":"81","upperLimit":"93"}]}]},{"title":"Day 1 (Men W) hSBA ≥ 1:8 (N=116,124)","categories":[{"measurements":[{"groupId":"OG000","value":"53","lowerLimit":"43","upperLimit":"62"},{"groupId":"OG001","value":"56","lowerLimit":"46","upperLimit":"65"}]}]},{"title":"Day 29 (Men W) hSBA ≥ 1:8 (N=116,124)","categories":[{"measurements":[{"groupId":"OG000","value":"96","lowerLimit":"90","upperLimit":"99"},{"groupId":"OG001","value":"97","lowerLimit":"92","upperLimit":"99"}]}]},{"title":"Day 1 (Men Y) hSBA ≥ 1:8 (N=117,125)","categories":[{"measurements":[{"groupId":"OG000","value":"38","lowerLimit":"30","upperLimit":"48"},{"groupId":"OG001","value":"38","lowerLimit":"29","upperLimit":"47"}]}]},{"title":"Day 29 (Men Y) hSBA ≥ 1:8 (N=117,125)","categories":[{"measurements":[{"groupId":"OG000","value":"93","lowerLimit":"87","upperLimit":"97"},{"groupId":"OG001","value":"94","lowerLimit":"89","upperLimit":"98"}]}]}]},{"type":"SECONDARY","title":"The hSBA Geometric Mean Titers Against N.Meningitidis Serogroups A,C,W and Y, When MenACWY-CRM is Concomitantly Administered With Tdap Vaccine Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The hSBA geometric mean titers (GMTs) against N.meningitidis serogroups A,C,W and Y, at baseline and at one month, following concomitant administration of MenACWY-CRM vaccine with Tdap vaccine, as compared to when MenACWY-CRM was given concomitantly with saline placebo.","populationDescription":"Analysis was done on per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"Day 1 (Men A)","categories":[{"measurements":[{"groupId":"OG000","value":"2.14","lowerLimit":"1.99","upperLimit":"2.31"},{"groupId":"OG001","value":"2.21","lowerLimit":"2.05","upperLimit":"2.38"}]}]},{"title":"Day 29 (Men A)","categories":[{"measurements":[{"groupId":"OG000","value":"34","lowerLimit":"23","upperLimit":"50"},{"groupId":"OG001","value":"50","lowerLimit":"34","upperLimit":"74"}]}]},{"title":"Day 1 (Men C) N=118,124","categories":[{"measurements":[{"groupId":"OG000","value":"4","lowerLimit":"3.23","upperLimit":"4.96"},{"groupId":"OG001","value":"3.92","lowerLimit":"3.16","upperLimit":"4.86"}]}]},{"title":"Day 29 (Men C) N=118,124","categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"58","upperLimit":"136"},{"groupId":"OG001","value":"92","lowerLimit":"60","upperLimit":"140"}]}]},{"title":"Day 1 (Men W) N=116,124","categories":[{"measurements":[{"groupId":"OG000","value":"11","lowerLimit":"7.7","upperLimit":"15"},{"groupId":"OG001","value":"9.49","lowerLimit":"6.93","upperLimit":"13"}]}]},{"title":"Day 29 (Men W) N=116,124","categories":[{"measurements":[{"groupId":"OG000","value":"73","lowerLimit":"54","upperLimit":"98"},{"groupId":"OG001","value":"77","lowerLimit":"57","upperLimit":"103"}]}]},{"title":"Day 1 (Men Y) N=117,125","categories":[{"measurements":[{"groupId":"OG000","value":"5.38","lowerLimit":"4.2","upperLimit":"6.89"},{"groupId":"OG001","value":"5","lowerLimit":"3.91","upperLimit":"6.39"}]}]},{"title":"Day 29 (Men Y) N=117,125","categories":[{"measurements":[{"groupId":"OG000","value":"73","lowerLimit":"54","upperLimit":"98"},{"groupId":"OG001","value":"70","lowerLimit":"52","upperLimit":"94"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratios of hSBA Titers Against N.Meningitidis Serogroups A,C,W and Y, When MenACWY-CRM is Concomitantly Administered With Tdap Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The geometric mean ratios (GMRs-day 29/day1)of post-vaccination versus pre- vaccination hSBA titers against N.meningitidis serogroups A,C,W and Y, when MenACWY-CRM vaccine is concomitantly administered with Tdap vaccine as compared to when MenACWY-CRM was given concomitantly with saline placebo.","populationDescription":"Analysis was done on per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratios","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"Men A","categories":[{"measurements":[{"groupId":"OG000","value":"16","lowerLimit":"11","upperLimit":"23"},{"groupId":"OG001","value":"23","lowerLimit":"16","upperLimit":"33"}]}]},{"title":"Men C (N=118,124)","categories":[{"measurements":[{"groupId":"OG000","value":"22","lowerLimit":"15","upperLimit":"33"},{"groupId":"OG001","value":"23","lowerLimit":"16","upperLimit":"35"}]}]},{"title":"Men W (N=116,124)","categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"4.84","upperLimit":"9.85"},{"groupId":"OG001","value":"8.09","lowerLimit":"5.69","upperLimit":"12"}]}]},{"title":"Men Y (N=117,125)","categories":[{"measurements":[{"groupId":"OG000","value":"14","lowerLimit":"9.41","upperLimit":"19"},{"groupId":"OG001","value":"14","lowerLimit":"9.79","upperLimit":"20"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA Seroresponse, When MenACWY-CRM is Concomitantly Administered With Tdap Compared to MenACWY-CRM Given Concomitantly With Saline Placebo","description":"The percentage of subjects showing an hSBA seroresponse against N.meningitidis serogroups A,C,W and Y, following concomitant administration of MenACWY-CRM vaccine with Tdap vaccine as compared to when MenACWY-CRM was given concomitantly with saline placebo.\n\nSeroresponse to MenACWY-CRM is defined as a pre-vaccination hSBA titer \\< 1:4 to a post-vaccination hSBA titer of ≥ 1:8 or a pre-vaccination hSBA titer ≥ 1:4 to a post-vaccination titer of at least four times the baseline hSBA titer.","populationDescription":"Analysis was done on per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"1 month after vaccination (Day 29)","groups":[{"id":"OG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"Men A","categories":[{"measurements":[{"groupId":"OG000","value":"74","lowerLimit":"65","upperLimit":"82"},{"groupId":"OG001","value":"80","lowerLimit":"72","upperLimit":"87"}]}]},{"title":"Men C (N=118, 124)","categories":[{"measurements":[{"groupId":"OG000","value":"82","lowerLimit":"74","upperLimit":"89"},{"groupId":"OG001","value":"78","lowerLimit":"70","upperLimit":"85"}]}]},{"title":"Men W (N=116, 124)","categories":[{"measurements":[{"groupId":"OG000","value":"58","lowerLimit":"48","upperLimit":"67"},{"groupId":"OG001","value":"59","lowerLimit":"50","upperLimit":"68"}]}]},{"title":"Men Y (N=117, 125)","categories":[{"measurements":[{"groupId":"OG000","value":"70","lowerLimit":"61","upperLimit":"78"},{"groupId":"OG001","value":"70","lowerLimit":"61","upperLimit":"78"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited Local and Systemic Adverse Events When Tdap is Concomitantly Administered With MenACWY-CRM Compared to When MenACWY-CRM is Concomitantly Administered With Saline Placebo","description":"The number of subjects reporting solicited local and systemic reactions following concomitant administration of MenACWY-CRM vaccine and Tdap vaccine as compared to when MenACWY-CRM vaccine was concomitantly administered with saline placebo.","populationDescription":"Analysis was done on the safety population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 1-7 after any vaccination","groups":[{"id":"OG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"357"}]}],"classes":[{"title":"Local","categories":[{"measurements":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"179"}]}]},{"title":"Injection site pain (MenACWY) site 1","categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"116"}]}]},{"title":"Injection site erythema (MenACWY) site 1","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"66"}]}]},{"title":"Injection site induration (MenACWY) site 1","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"59"}]}]},{"title":"Injection site pain (Tdap or saline) site 2","categories":[{"measurements":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"57"}]}]},{"title":"Injection site erythema (Tdap or saline) site 2","categories":[{"measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"37"}]}]},{"title":"Injection site induration (Tdap or saline) site 2","categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"23"}]}]},{"title":"Systemic","categories":[{"measurements":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"171"}]}]},{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"47"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"28"}]}]},{"title":"Malaise","categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"43"}]}]},{"title":"Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"79"}]}]},{"title":"Arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"40"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"128"}]}]},{"title":"Fever ≥ 38°C","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"14"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"33"}]}]},{"title":"Stayed home due to reaction (N=358,357)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"}]}]},{"title":"Analgesic Antipyretic medication used","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"31"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited Local and Systemic Adverse Events When Tdap is Concomitantly Administered With MenACWY-CRM Compared to When Tdap is Concomitantly Administered With Saline Placebo","description":"The number of subjects reporting solicited local and systemic reactions following concomitant administration of MenACWY-CRM vaccine and Tdap vaccine as compared to when Tdap was concomitantly administered with saline placebo","populationDescription":"Analysis was done on the safety population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 1-7 after any vaccination","groups":[{"id":"OG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"Tdap + Saline","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"353"}]}],"classes":[{"title":"Local","categories":[{"measurements":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"282"}]}]},{"title":"Injection site pain (Tdap) site 2","categories":[{"measurements":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"246"}]}]},{"title":"Injection site erythema (Tdap) site 2","categories":[{"measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"103"}]}]},{"title":"Injection site induration (Tdap) site 2","categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"118"}]}]},{"title":"Injection site pain (MenACWY or saline) site 1","categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"41"}]}]},{"title":"Injection site erythema (MenACWY or saline) site 1","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"34"}]}]},{"title":"Injection site induration(MenACWY or saline)site1","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"27"}]}]},{"title":"Systemic","categories":[{"measurements":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"202"}]}]},{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"41"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"35"}]}]},{"title":"Malaise","categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"57"}]}]},{"title":"Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"127"}]}]},{"title":"Arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"60"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"110"}]}]},{"title":"Fever ≥ 38°C","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"39"}]}]},{"title":"Stayed home due to reaction (N=358,353)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"}]}]},{"title":"Analgesic Antipyretic medication used","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"38"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events When Tdap is Concomitantly Administered With MenACWY-CRM Compared to MenACWY-CRM or Tdap Concomitantly Administered With Saline Placebo","description":"The number of subjects reporting any unsolicited adverse events (AEs) when Tdap is concomitantly administered with MenACWY-CRM as compared to when MenACWY-CRM vaccine or Tdap vaccine was concomitantly administered with saline placebo.","populationDescription":"This analysis was done on the safety population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Throughout the study (Day 1 to Day 181)","groups":[{"id":"OG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap vaccine and MenACWY-CRM vaccine concomitantly, in separate arms"},{"id":"OG001","title":"Tdap + Saline","description":"Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms"},{"id":"OG002","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"353"},{"groupId":"OG002","value":"357"}]}],"classes":[{"title":"Any AE (Day 1 to 29)","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"48"}]}]},{"title":"Possibly/probably related AE (Day 1 to 29)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"Serious AEs (Day 1 to 29)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"AE's leading to discontinuation (Day 1 to 29)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Possibly/probably related SAE(Day 1 to 29)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Death ( Day 1 to 29)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any AE (Day 30 to 181)","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"39"}]}]},{"title":"Possibly/probably related AE (Day 30 to 181)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Serious AEs (Day 30 to 181)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"AE's leading to discontinuation (Day 30 to 181)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Possibly/probably related SAE (Day 30 to 181)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Death (Day 30 to 181)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All serious adverse events were collected throughout the study (Day 1-181). All solicited events were collected from Day 1-7 post vaccination; unsolicited adverse events were collected from Day 1-181.","description":"There were 3 subjects who withdrew consent (2 subjects in the Tdap+MenACWY-CRM group and 1 subject in the Tdap+Saline group) prior to visit one of the study and thus were not included in the safety analyses for this section.","eventGroups":[{"id":"EG000","title":"Tdap + MenACWY-CRM","description":"Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms","seriousNumAffected":1,"seriousNumAtRisk":359,"otherNumAffected":297,"otherNumAtRisk":359},{"id":"EG001","title":"Tdap + Saline","description":"Subjects received Tdap vaccine and saline (placebo)concomitantly, in separate arms","seriousNumAffected":2,"seriousNumAtRisk":353,"otherNumAffected":309,"otherNumAtRisk":353},{"id":"EG002","title":"MenACWY-CRM + Saline","description":"Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms","seriousNumAffected":0,"seriousNumAtRisk":357,"otherNumAffected":238,"otherNumAtRisk":357}],"seriousEvents":[{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":359},{"groupId":"EG001","numAffected":1,"numAtRisk":353},{"groupId":"EG002","numAffected":0,"numAtRisk":357}]},{"term":"Heat stroke","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":359},{"groupId":"EG001","numAffected":0,"numAtRisk":353},{"groupId":"EG002","numAffected":0,"numAtRisk":357}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":359},{"groupId":"EG001","numAffected":1,"numAtRisk":353},{"groupId":"EG002","numAffected":0,"numAtRisk":357}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":359},{"groupId":"EG001","numAffected":38,"numAtRisk":353},{"groupId":"EG002","numAffected":31,"numAtRisk":357}]},{"term":"Chills","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":359},{"groupId":"EG001","numAffected":41,"numAtRisk":353},{"groupId":"EG002","numAffected":47,"numAtRisk":357}]},{"term":"Injection site erythema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":119,"numAtRisk":359},{"groupId":"EG001","numAffected":110,"numAtRisk":353},{"groupId":"EG002","numAffected":83,"numAtRisk":357}]},{"term":"Injection site induration","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":125,"numAtRisk":359},{"groupId":"EG001","numAffected":131,"numAtRisk":353},{"groupId":"EG002","numAffected":72,"numAtRisk":357}]},{"term":"Injection site pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":259,"numAtRisk":359},{"groupId":"EG001","numAffected":262,"numAtRisk":353},{"groupId":"EG002","numAffected":139,"numAtRisk":357}]},{"term":"Malaise","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":67,"numAtRisk":359},{"groupId":"EG001","numAffected":57,"numAtRisk":353},{"groupId":"EG002","numAffected":43,"numAtRisk":357}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":359},{"groupId":"EG001","numAffected":14,"numAtRisk":353},{"groupId":"EG002","numAffected":21,"numAtRisk":357}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":359},{"groupId":"EG001","numAffected":60,"numAtRisk":353},{"groupId":"EG002","numAffected":40,"numAtRisk":357}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":119,"numAtRisk":359},{"groupId":"EG001","numAffected":128,"numAtRisk":353},{"groupId":"EG002","numAffected":80,"numAtRisk":357}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":131,"numAtRisk":359},{"groupId":"EG001","numAffected":113,"numAtRisk":353},{"groupId":"EG002","numAffected":136,"numAtRisk":357}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Posting Director","organization":"Novartis Vaccines and Diagnostics","email":"RegistryContactVaccinesUS@novartis.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D008589","term":"Meningococcal Infections"},{"id":"D008585","term":"Meningitis, Meningococcal"},{"id":"D008581","term":"Meningitis"}],"ancestors":[{"id":"D016870","term":"Neisseriaceae Infections"},{"id":"D016905","term":"Gram-Negative Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"},{"id":"D016920","term":"Meningitis, Bacterial"},{"id":"D020806","term":"Central Nervous System Bacterial Infections"},{"id":"D002494","term":"Central Nervous System Infections"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D000090862","term":"Neuroinflammatory Diseases"}]}},"hasResults":true}